Trinity Biotech gets Nasdaq bid price warning
Rhea-AI Filing Summary
Trinity Biotech plc received a notice from Nasdaq that its American Depositary Shares are not in compliance with the Nasdaq Global Select Market’s minimum bid price requirement of $1.00 per share, after trading below this level for 30 consecutive business days.
The company has 180 calendar days, until August 10, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing, and the ADSs continue to trade on the Nasdaq Global Select Market under the symbol TRIB.
If compliance is not regained within this period, the company may qualify for additional time on The Nasdaq Capital Market if it meets the minimum value of publicly held shares requirement of $15,000,000 and other initial listing standards. Management is monitoring the share price and evaluating options to maintain the listing.
Positive
- None.
Negative
- Nasdaq minimum bid price non-compliance raises delisting risk: Trinity Biotech’s ADSs have stayed below Nasdaq’s $1.00 minimum bid for 30 consecutive business days, triggering a formal notice and a 180‑day cure period, after which continued listing may depend on stricter criteria or could be at risk.
Insights
Nasdaq bid-price deficit puts Trinity Biotech’s listing at risk.
Trinity Biotech has fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after 30 consecutive business days below that level. While trading on the Nasdaq Global Select Market continues for now, the company faces a defined 180‑day window to cure the deficiency.
To regain compliance, the ADS closing bid must reach at least $1.00 for ten consecutive business days before August 10, 2026. If that fails, continued listing could depend on meeting The Nasdaq Capital Market’s initial standards, including a publicly held share value of at least $15,000,000, and securing a second compliance period.
Management states it is actively monitoring the ADS price and evaluating options to address the issue, while expecting trading on the Nasdaq Global Select Market to continue during the grace period. Actual outcomes will hinge on market performance and any remedial actions the company undertakes within the specified timelines.
FAQ
What Nasdaq issue did Trinity Biotech plc (TRIB) disclose in this 6-K?
Trinity Biotech disclosed that Nasdaq notified the company it is not in compliance with Listing Rule 5450(a)(1) because its ADSs closed below $1.00 for 30 consecutive business days, triggering a formal minimum bid price deficiency notice and a defined cure period.
How long does Trinity Biotech (TRIB) have to regain Nasdaq bid price compliance?
Trinity Biotech has 180 calendar days, until August 10, 2026, to regain compliance. Its ADS closing bid must be at or above $1.00 per share for at least ten consecutive business days within this grace period to satisfy Nasdaq requirements.
Does the Nasdaq non-compliance notice immediately affect Trinity Biotech’s listing?
The notice has no immediate effect on listing. Trinity Biotech states its ADSs will continue trading on the Nasdaq Global Select Market under the symbol TRIB while it works within the 180‑day grace period to restore compliance with the minimum bid price rule.
What happens if Trinity Biotech fails to meet the Nasdaq minimum bid price by August 10, 2026?
If compliance is not regained by August 10, 2026, Trinity Biotech may still receive additional time if it meets The Nasdaq Capital Market’s initial listing standards, including at least $15,000,000 in publicly held shares, and commits in writing to cure the bid price deficiency.
What actions is Trinity Biotech’s management considering after the Nasdaq notice?
Management says it is actively monitoring the ADS bid price and evaluating options to cure the Nasdaq deficiency within the grace period. The company expects its ADSs to remain listed and trading on the Nasdaq Global Select Market while it assesses and implements potential remedies.
What is Nasdaq Listing Rule 5450(a)(1) mentioned by Trinity Biotech (TRIB)?
Nasdaq Listing Rule 5450(a)(1) requires securities listed on the Nasdaq Global Select Market to maintain a minimum bid price of $1.00 per share. Trinity Biotech’s ADSs stayed below this threshold for 30 consecutive business days, leading to the current non-compliance notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232, 333-253070 and 333-292753).
EXPLANATORY NOTE
On February 11, 2026, the Company issued a press release announcing it had received a notice from the Nasdaq Stock Market LLC (“Nasdaq”)
that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company’s American depositary shares (“ADSs”)
for the last 30 consecutive business days. The Company has a period of 180 calendar days, or until August 10, 2026 to regain compliance with Nasdaq Listing Rule 5450(a)(1). A copy of the press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
|
Exhibit
|
Description
|
|
|
99.1
|
|
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select
Requirement for Nasdaq Minimum Bid Price Requirement
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
TRINITY BIOTECH PLC
|
|
|
|
|
|
Trinity Biotech plc
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Paul Murphy
|
|
|
|
|
Paul Murphy
|
|
|
|
|
Interim Chief Financial Officer
|
|
Date: February 13, 2026
Exhibit 99.1
| Contact: |
Trinity Biotech plc
Paul Murphy (353)-1-2769800
|
RedChip Companies Inc.
Dave Gentry, CEO
(1)-407-644-4256
(1)-800-RED-CHIP (733-2447)
TRIB@redchip.com
|
Trinity Biotech Receives Non-Compliance Notice Regarding
Nasdaq Global Select Requirement for Nasdaq Minimum Bid
Price Requirement
DUBLIN, Ireland (February 13, 2026) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human
diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that
listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company’s American Depositary Shares (“ADSs”) for the last 30 consecutive business days.
This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until August 10, 2026, to regain compliance with the minimum bid price requirement. To regain
compliance, the closing bid price of the Company’s ADSs must meet or exceed $1.00 for at least ten consecutive business days during this 180-calendar day period. In the event the Company does not regain compliance, the Company may be eligible for
additional time if it meets the continued listing requirement for minimum value of publicly held shares (“MVPHS”) ($15,000,000) and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price and provides
written notice to Nasdaq of its intention to cure the deficiency during the second compliance period.
Management intends to actively monitor the bid price for its ADSs and to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company
will continue to be listed and trade on the Nasdaq Global Select Market. The Company’s management is evaluating various options available to regain compliance and maintain its continued listing.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited
to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity
Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of
similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of
our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its
variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to
Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products
and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments
manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and
risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from
time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any
forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures
and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the
biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the
level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For
further information, please see the Company's website: www.trinitybiotech.com.